Non-Insulin Therapies For Diabetes Market 2024 : Industry Analysis, Trends, Segmentation, Regional Overview And Forecast 2033

Spread the love

Overview and Scope
The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Sizing and Forecast
The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $18.71 billion in 2023 to $19.98 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing diabetes prevalence, increasing awareness of diabetes management, rise in healthcare expenditure, shift in lifestyle changes leading to higher incidence rates, surge in diagnosis, increasing government initiatives for diabetes care, and increasing investment in pharmaceutical R&D.

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $26.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing awareness of diabetes management, growing adoption of combination therapies, expanding geriatric population, increasing healthcare expenditure, expansion of telemedicine, and growing preference for oral medications. Major trends in the forecast period include advancements in oral and injectable medications, advancements in drug delivery systems, advancements in oral peptide delivery, adoption of telemedicine and digital health solutions, and advancements in combination therapies.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Segmentation & Regional Insights
The non-insulin therapies for diabetes market covered in this report is segmented –

1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications

North America was the largest region in the non-insulin therapies for diabetes market in 2023. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp

Major Driver Impacting Market Growth
The increase in the prevalence of diabetes is expected to propel the growth of non-insulin therapies for the diabetes market going forward. Diabetes is a chronic medical condition characterized by high blood glucose (sugar) levels. It occurs when the body cannot produce enough insulin or properly use the insulin it makes. The cases of diabetes is growing due to sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited access to healthcare, and environmental factors. Non-insulin therapies for diabetes help treat the condition by improving insulin sensitivity, reducing glucose production in the liver, increasing glucose uptake in muscle cells, and enhancing overall glycemic control. For instance, in 2021, according to the International Diabetes Federation, a US-based umbrella organization, approximately 537 million adults (20-79 years) were living with diabetes in the world. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increase in the prevalence of diabetes will drive the non-insulin therapies for diabetes market.

Key Industry Players
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

The non-insulin therapies for diabetes market report table of contents includes:

1. Executive Summary

2. Non-Insulin Therapies For Diabetes Market Characteristics

3. Non-Insulin Therapies For Diabetes Market Trends And Strategies

4. Non-Insulin Therapies For Diabetes Market – Macro Economic Scenario

5. Global Non-Insulin Therapies For Diabetes Market Size and Growth
………

32. Global Non-Insulin Therapies For Diabetes Market Competitive Benchmarking

33. Global Non-Insulin Therapies For Diabetes Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market

35. Non-Insulin Therapies For Diabetes Market Future Outlook and Potential Analysis

36. Appendix

Contact Us: